Of course thatâs your contention. Youâre entering your design era. You just discovered Figma, watched a 12-minute video on neumorphism, and youâre tweeting screenshots of UI like itâs sacred geometry.
Right now, itâs all about spacing systems, atomic components, and arguing about whether a button should have an 8px or 12px radius.
Next month, youâll read Don't Make Me Think, start saying âcognitive loadâ in casual conversation, and wireframe every app idea in grayscale.
By fall, youâll build a design system from scratch, name it something like âQuartz,â and enforce uppercase nav labels like itâs federal law.
Next year, youâll be in a Slack fight over whether shadows are expressive or lazy, while quietly editing 42 variants of the same icon.
Youâll use words like âsemantic affordanceâ to describe a modal that closes when you click outside of it.
You havenât even begun to suffer yet. Youâll be knee-deep in Jira tickets, debating whether a tooltip is a feature or a cry for help.
You havenât spent 3 hours naming a color âCoconut Mistâ only to have the engineer call it #a0a0a0 and move on.
You think this is about pixels.
Itâs not.
Itâs about shaping intention into formâso clearly and usefully that the function reveals itself, no matter the stack, tool, or screen.
Then weâll talk design.
@NiuSanford@ShaalanBeg Thanks! For pain panc dosing, do you draw plexus? Doesnât seem like it was done on study (maybe Iâm wrong?) but should be safe from a dosing standpoint
0/ @multicoin has been investing in SOL since May 2018
In that time, we have published 4 theses to share our views on how we think about Solana
Today I'm excited to share the 5th in that series:
The Solana Thesis: Internet Capital Markets
(link in next tweet)
I am so excited and happy for another amazing @RarebreedVC portfolio company @unspun_io. After announcing a partnership with @Walmart they have now gone on to close their $32M oversubscribed series B round
https://t.co/a0W9BH6g3O
@NiuSanford Kind of reminds me of prostate trials w neoadjuvant adt prior to prostatectomy. Higher rates of negative margins but no improvement of biochemical recurrence..